Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298723 | 0.89 | KDM4E (0.41) | SMN1; SMN2POLBLMNACYP1A2L3MBTL1 | |
| SCHEMBL10467741 | 0.83 | L3MBTL1 (0.53) | LMNACYP1A2L3MBTL1TDP1ALDH1A1 | |
| SCHEMBL2641374 | 0.82 | SMN1; SMN2 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11512639 | 0.82 | SMN1; SMN2 (0.59) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5255563 | 0.79 | MAOA (0.49) | SMN1; SMN2LMNAL3MBTL1RAB9AKDM4E | |
| SCHEMBL1553402 | 0.79 | CA1 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6811036 | 0.79 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL1632207 | 0.79 | KDM4E (0.50) | SMN1; SMN2LMNACYP1A2RAB9AKDM4E | |
| SCHEMBL29679041 | 0.79 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6211409 | 0.79 | L3MBTL1 (0.33) | SMN1; SMN2POLBLMNACYP1A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | claimed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | claimed |
| JP-H08504795-A | — | — | 1996-05-21 | — | — | JP | claimed |
| EP-0675895-A1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER. | FABRE PIERRE COSMETIQUE (FR) | 1995-10-11 | — | — | EP | claimed |
| EP-0469888-B1 | Amidobenzenes | ICI PLC (GB) | 1994-09-28 | — | — | EP | claimed |
| WO-1994014829-A1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1994-07-07 | — | — | WO | claimed |
| US-5250570-A | Aldose reductase inhibitors for controlling side effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-05 | — | — | US | claimed |
| EP-0469888-A1 | Amidobenzenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-05 | — | — | EP | claimed |
| US-4178445-A | 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-12-11 | — | — | US | claimed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-0299728-A2 | Carbonylation process for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4778884-A | REACTING TRIFLUOROMETHYLSULFONYLOXY COMPOUND WITH LITHIUM HALIDE IN APROTIC POLAR SOLVENT | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4673737-A | ANTIBIOTICS/ | HARVARD UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |
| EP-0211540-A1 | Intermediates and process for antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | CA12 1245/4885CA1 1364/4885CA2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.